je.st
news
Tag: insomnia
Christina Applegate and Merck Urge Insomnia Sufferers to Learn Why Theyre So Awake
2016-04-28 14:00:23| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. Christina Applegate Shares Personal Struggle with Insomnia and Encourages Others to Educate Themselves about the Wake and Sleep Systems in the Brain KENILWORTH, N.J. Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced it is teaming up with Emmy Award-winning actress Christina Applegate to educate the millions of Americans struggling with insomnia. An insomnia sufferer for much of her adult life, Applegate is sharing her personal experience to inspire others to learn more about how to get the sleep they need. Language: English read more
Tags: learn
why
christina
urge
Apples iOS 9.3 update tackles screen-related insomnia with Night Shift
2016-01-12 14:36:16| Extremetech
Not only will this point-release have a handful of meaningful tweaks to existing apps, but there are two new major features that could change how many of us use our phones and tablets.
Tags: night
update
shift
apples
Light emitting glasses herald new era for insomnia treatment
2015-07-01 18:30:33| Extremetech
A new type of light emitting glasses are shaking things up for the treatment of insomnia. Expect more health wearables to come.
Tags: light
treatment
era
glasses
Mercks Insomnia Medicine BELSOMRA (suvorexant) C-IV, the First and Only Orexin Receptor Antagonist, Now Available in the United States
2015-02-03 14:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that BELSOMRA (suvorexant) is now available at pharmacies in the United States for the treatment of insomnia in adults who have difficulty falling asleep and/or staying asleep. BELSOMRA is the only orexin receptor antagonist approved for the treatment of insomnia in the United States. Orexin is one of the many neurotransmitters in the brain involved in promoting wakefulness, and BELSOMRA selectively blocks orexin receptors. Language: English Contact: Merck & Co., Inc.Media:Pam Eisele, 267-305-3558orMegan Wilkinson, 267-305-6463orInvestor:Justin Holko, 908-740-1879orJoe Romanelli, 908-740-1986 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: the
united
states
medicine
FDA Approves BELSOMRA (suvorexant) for the Treatment of Insomnia
2014-08-13 22:49:00| Merck.com - Product News
Dateline City: WHITEHOUSE STATION, N.J. BELSOMRA expected to be available in late 2014 or early 2015 WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved BELSOMRA (suvorexant) for adults with insomnia who have difficulty falling asleep and/or staying asleep. BELSOMRA (pronounced bell-SOM-rah) is a highly selective antagonist for orexin receptors. Orexin is a neurotransmitter found in a specific part of the brain that can help keep a person awake. Language: English Contact: MerckMedia Contacts:Pam Eisele, 267-305-3558Megan Wilkinson, 267-305-6463orInvestor Contacts:Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: treatment
fda
approves
insomnia